DDInter45 DDInter927
A phenothiazine derivative that is used as an antipruritic.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Alimemazine {u} (Compound) resembles {v} (Compound) Acetophenazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orphenadrine
Alimemazine {u} (Compound) resembles {v} (Compound) Pheniramine
Alimemazine {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Alimemazine {u} (Compound) binds {v} (Gene) CYP3A4
Alimemazine {u} (Compound) upregulates {v} (Gene) CHEK2
Alimemazine {u} (Compound) downregulates {v} (Gene) PDHX
Alimemazine {u} (Compound) causes {v} (Side Effect) Respiratory depression
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium hydroxide
Alimemazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Alimemazine (Compound) resembles Acetophenazine (Compound)
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Alimemazine (Compound) resembles Pheniramine (Compound)
Alimemazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Alimemazine (Compound) binds CYP3A4 (Gene)
Alimemazine (Compound) upregulates CHEK2 (Gene)
Alimemazine (Compound) downregulates PDHX (Gene)
Alimemazine (Compound) causes Respiratory depression (Side Effect)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate